Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Mazières, J; Drilon, A; Lusque, A; Mhanna, L; Cortot, A B; Mezquita, L; Thai, A A; Mascaux, C; Couraud, S; Veillon, R; Van Den Heuvel, M; Neal, J; Peled, N; Früh, M; T L, Ng; Gounant, V; Popat, S; Diebold, J; Sabari, J; Zhu, V W; Rothschild, S I; Bironzo, P; Martinez, A; Curioni-Fontecedro, A; Rosell, R; Lattuca-Truc, M; Wiesweg, M; Besse, B; Solomon, B; Barlesi, F; Schouten, R D; Wakelee, H; Camidge, D R; Zalcman, G; Novello, S; S I, Ou; Milia, J; Gautschi, O

doi:10.1093/annonc/mdz167

Anti-PD1/PD-L1 directed immune-checkpoint-inhibitors (ICI) are widely used to treat patients with advanced non-small cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations is poorly characterized. The aim of our study was to address the efficacy of ICI in the context of oncogenic addiction.

Titolo:	Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
Autori Riconosciuti:	Mazières, J Drilon, A Lusque, A Mhanna, L Cortot, A B Mezquita, L Thai, A A Mascaux, C Couraud, S Veillon, R Van Den Heuvel, M Neal, J Peled, N Früh, M Ng, T L Gounant, V Popat, S Diebold, J Sabari, J Zhu, V W Rothschild, S I BIRONZO, Paolo Martinez, A Curioni-Fontecedro, A Rosell, R Lattuca-Truc, M Wiesweg, M Besse, B Solomon, B Barlesi, F Schouten, R D Wakelee, H Camidge, D R Zalcman, G NOVELLO, Silvia Ou, S I Milia, J Gautschi, O mostra contributor esterni nascondi contributor esterni
Autori:	Mazières, J; Drilon, A; Lusque, A; Mhanna, L; Cortot, A B; Mezquita, L; Thai, A A; Mascaux, C; Couraud, S; Veillon, R; Van Den Heuvel, M; Neal, J; Peled, N; Früh, M; Ng, T L; Gounant, V; Popat, S; Diebold, J; Sabari, J; Zhu, V W; Rothschild, S I; Bironzo, P; Martinez, A; Curioni-Fontecedro, A; Rosell, R; Lattuca-Truc, M; Wiesweg, M; Besse, B; Solomon, B; Barlesi, F; Schouten, R D; Wakelee, H; Camidge, D R; Zalcman, G; Novello, S; Ou, S I; Milia, J; Gautschi, O
Data di pubblicazione:	2019
Abstract:	Anti-PD1/PD-L1 directed immune-checkpoint-inhibitors (ICI) are widely used to treat patients with advanced non-small cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations is poorly characterized. The aim of our study was to address the efficacy of ICI in the context of oncogenic addiction.
Pagina iniziale:	///
Pagina finale:	///
Digital Object Identifier (DOI):	10.1093/annonc/mdz167
Parole Chiave:	Immunotherapy-lung cancer-oncogenic addiction
Rivista:	ANNALS OF ONCOLOGY
Appare nelle tipologie:	03A-Articolo su Rivista

File in questo prodotto:

File	Descrizione	Tipologia	Licenza
mdz167.pdf		POSTPRINT (VERSIONE FINALE DELL’AUTORE)		Open Access Visualizza/Apri

Utilizza questo identificativo per citare o creare un link a questo documento:
http://hdl.handle.net/2318/1703925

Citazioni

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

CINECA IRIS Institutional Research Information System

File in questo prodotto: